[Treatment of metastatic kidney cancer in elderly subjects].
Treatment of metastatic kidney cancer in elderly subjects is identical to treatment of younger subjects. Whereas cytokines were classically contraindicated in patients over 70 or 75 years (notably IL2), new targeted therapies have been evaluated and found to be usable with no age limit, and all of the phase III studies have included patients 80 years old and older. Overall, there seems to be no difference in efficacy based on age (except perhaps for temsirolimus). As for tolerance, it is satisfactory for all therapies. Dose reduction is slightly more frequent, which calls for caution, notably with sunitinib, for which a direct correlation between the dose administered and efficacy has been reported. Given the data available today, no dose adaptation in relation to age is recommended in metastatic renal cancer.
Escudier
B
B
Unité d'Immunothérapie, Institut Gustave Roussy, Rue Camille Desmoulins, 94805 Villejuif, France. escudier@igr.fr
Paparel
P
P
Neuzillet
Y
Y
Long
J-A
JA
Rioux-Leclercq
N
N
Correas
J-M
JM
Lang
H
H
Poissonnier
L
L
Baumert
H
H
Mejean
A
A
Patard
J-J
JJ
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D009362:Neoplasm Metastasis
D000970:Antineoplastic Agents